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E-mail address: sarah.everitt@petermac.org (S. EveBackground and purpose: To investigate the impact of treatment delays on radiation therapy (RT) target
volumes and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) who underwent
two baseline FDG PET/CT scans.
Material and methods: Patients underwent a staging (PET1) and RT planning (PET2) FDG PET/CT scan. At
PET1 all patients were eligible for radical chemo-RT. OS and progression-free survival (PFS) were com-
pared for patients remaining eligible for radical RT and those treated palliatively because PET2 showed
progression. RT target volumes were contoured using PET1 and PET2. Normal tissue doses were com-
pared for patients remaining eligible for radical RT.
Results: Eighty-two patients underwent PET2 scans between October 2004 and February 2007. Of these,
21 had a prior PET1 scan, median 23 days apart (range 8–176 days). Six patients (29%) were unsuitable for
radical RT after PET2; ﬁve received palliative treatment and one received no treatment. Patients treated
palliatively had signiﬁcantly worse OS and PFS than patients treated radically p < 0.001. Mean RT tumour
volume increased from 105cc to 198cc (p < 0.005) between scans.
Conclusions: Disease progression while awaiting initiation of curative RT in NSCLC is associated with lar-
ger treatment volumes and worse survival.
Crown Copyright  2013 Published by Elsevier Ireland Ltd.
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Open access under CC BY-NC-ND license.Although tumour doubling times vary widely, human epithelial
cancers grow inexorably and the probability that nodal and distant
metastasis will occur increases with elapsing time [1]. Lung cancer
is often rapidly growing with estimated doubling times of 45–
207 days [1–3]. In patients with non-small cell lung cancer (NSCLC)
it is likely that delays in commencing deﬁnitive radiotherapy (RT)
will ultimately lead to worse survival due to interval disease
progression.
Principal sources of treatment delays include establishing a can-
cer diagnosis and waiting times for multi-disciplinary consultation,
staging investigations and treatment itself. In RT candidates with
head and neck cancer and NSCLC, these delays can result in clini-
cally signiﬁcant tumour progression [3–7]. However, evidence doc-
umenting the impact of treatment delays on actual patient
outcomes is limited. Wang et al. [8] reported that treatment delays
were associated with a lower probability of survival in NSCLCevier Ireland Ltd.
Cancer Centre, Locked Bag 1
ritt).
Open access under Cpatients who survived more than ﬁve years [8]. Although it may
seem reasonable to assume that shorter waiting times necessarily
lead to better patient outcomes, others have reported an associa-
tion between shorter waiting times and poorer survival [9–12].
An absence of effect on disease stage and patient survival has also
been reported [13,14].
Signiﬁcant delays combined with rapid tumour growth must
also inevitably result in larger target volumes for irradiation. Larger
RT ﬁelds increase the volume of adjacent organs at risk (OAR) being
irradiated, thereby increasing the incidence and the severity of
radiation induced toxicities and therapy related mortalities. Fur-
thermore, long delays between the acquisition of a RT planning
scan and treatment commencement may result in a geographic
miss if RT ﬁelds no longer encompass the entire tumour.
We have previously studied stage progression and tumour dou-
bling times in patients with NSCLC using serial pre-treatment 18F-
ﬂuorodeoxyglucose (FDG) positron emission tomography (PET)
and computed tomography (CT) scans, reporting signiﬁcant inter-
scan disease progression in 11 (39%) patients [3]. We have now ex-
tended our investigation to explore the impact of treatment delaysC BY-NC-ND license.
Table 1
Patient characteristics.
Frequency n = 21 Percent %
Age (years)
Median 68
Range 45–87
Gender
Males 14 67
Histology
Adenocarcinoma 7 33
Squamous or epidermoid carcinoma 10 48
Large cell carcinoma 1 5
Unclassiﬁed 3 14
Tumour stage (UICC 6th edition) PET1 n (%) PET2 n (%)
Stage IA 1 (5) 0
Stage IB 5 (24) 4 (19)
Stage IIB 2 (9) 2 (10)
Stage IIIA 9 (43) 9 (43)
Stage IIIB 4 (19) 3 (14)
Stage IV 0 3 (14)
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and doses received by OAR in those patients who actually received
radical RT.
Methods and materials
This is a sub-analysis of a prospective trial of PET/CT in RT plan-
ning in NSCLC, approved by the Peter MacCallum Cancer Centre
and Monash University ethics committees. All patients provided
written informed consent. Eligible patients with a histologically
conﬁrmed diagnosis of NSCLC received two pre-treatment FDG-
PET/CT scans at our centre and were candidates for radical RT after
the ﬁrst scan (PET1). In accordance with our unit protocol, a second
scan (PET2) was systematically indicated if PET1 was acquired
more than four weeks prior and/or without precise RT immobilisa-
tion. Changes in clinical management were made if new clinical
information was derived from PET2.
Both scans were performed on an integrated PET/CT scanner at
our centre (Discovery LS scanner, GE Medical Systems, Waukesha,
WI). As previously described, patients fasted prior to injection of
FDG and were scanned in a supine position from lower neck to pel-
vis [3]. Scans were reported by an experienced PET/CT specialist
(RH) and discussed at a multidisciplinary meeting. A radiation
oncologist (NP) liaised closely with the PET/CT specialist to identify
all regions of gross disease for every patient [15]. Scans were dis-
played on Focal (CMS Inc., St. Louis, MO, USA), with the CT data
as the primary study-set (window/level 500/0) and PET data as
the secondary study-set (window/level individualised, as previ-
ously described [3]). Gross tumour volume (GTV) deﬁned the pri-
mary tumour alone. GTV1 and GTV2 classiﬁed the closest and
next closest regional lymph node stations to the primary tumour,
respectively. A 15 mmmargin was applied to all GTV(s) to generate
a PTV for each scan.
For patients remaining radical candidates, a dosimetrist (SE)
generated separate plans for the PET1 and PET2 PTVs. Dosimetry
was performed according to ICRU recommendations using Xio
computerised planning system (CMS Inc., St. Louis, MO, USA),
6 MV photons and a fast superposition algorithm [16,17]. All pa-
tients were treated according to the plan generated for PET2 to
60 Gy in 30 fractions over six weeks with concomitant chemother-
apy (either; weekly carboplatin (area under curve [AUC], 2 IV) and
paclitaxel (45 mg/m2 IV) or cisplatin (50 mg/m2 IV) on days 1, 8, 29
and 36 and etoposide (50 mg/m2 IV) daily days 1–5 and 29–33).
For this study the PET2 plan was applied to the PET1 PTV. Beam
apertures were adjusted to account for PTV changes. Beam angles
and weightings were maintained where possible to allow an accu-
rate comparison of any changes in OAR doses due to tumour
growth, rather than planning parameters themselves. OAR dosi-
metrics included normal lungs (lung volume receiving 20 Gy
(LV20) 635%, LV30 630% and mean lung dose (MLD) 620 Gy), max-
imum spinal canal dose 646 Gy, oesophagus (OV50 and MOD) and
heart (HV40 and MHD).
Overall survival (OS) was measured from the PET1 date until
death due to any cause. Progression free survival (PFS) was mea-
sured from treatment commencement until any conﬁrmed disease
progression, or death due to any cause, whichever occurred ﬁrst.
For patients with progression detected on PET2, disease progres-
sion deﬁnes the next progression beyond that observed on PET2.
The analysis closeout date was 30th November, 2007.
Comparisons of OS and PFS between radical and palliative pa-
tients were made using the log-rank test. The Kaplan–Meier (prod-
uct-limit) method was used to estimate OS and PFS survival curves.
The following paired 2-sample testing procedure was conducted
for each GTV volume pair (PET1 vs. PET2) and OAR dosimetric
being compared. Firstly the assumption of normally distributed
data within groups was tested. If not rejected, a Student’s t-testwas performed. If the assumption of normality was rejected the
data were log-transformed and the assumption of normality tested
on the transformed data. If this test failed to reject the assumption
of normality, a t-test was performed on the log-transformed data.
Otherwise the non-parametric Wilcoxon test was performed.
Group means are based on patients for whom data were present
for the volume under consideration in both scans in the paired test.
Estimates of the differences between group means are presented,
together with 95% conﬁdence intervals (CI) of the estimates. All
p-values are 2-sided. S-Plus and R (S-PLUS 2000 Professional Re-
lease 2, Mathsoft Inc., and R Development Core Team (2012). R:
A language and environment for statistical computing. R Founda-
tion for Statistical Computing, Vienna, Austria. ISBN 3-900051-
07-0, URL http://www.R-project.org/) were used for statistical
analyses.
Results
Eighty-two patients entered the prospective planning study be-
tween October 2004 and February 2007. Of these, 21 (26%) under-
went two PET/CT scans at our centre. Patient characteristics are
presented in Table 1. PET2 was requested with RT immobilisation
for 13 (62%) patients when PET1 was less than four weeks prior
and for eight (38%) patients when PET1 was more than four weeks
prior. For all patients, the median inter-scan period was 23 days
(range 8–176 days). As previously reported, reasons for obtaining
a second PET/CT scan included 18 (86%) patients who were initially
surgical candidates and were not positioned for RT and two (10%)
patients where lung cancer was an incidental ﬁnding on PET/CT
imaging performed for another purpose [3]. One patient (with an
outlying inter-scan interval of 176 days) initially declined surgery
and later requested RT.
Due to disease progression detected on PET2, six (29%) patients
received palliative treatment. The median inter-scan period for
these patients was 22 days (range 9–65 days). Palliative treatment
was necessitated due to advanced loco-regional disease andmetas-
tases (two patients), metastases alone (one patient), advanced
loco-regional disease that could not be safely encompassed in
60 Gy radical dose (two patients) and deteriorating performance
status (one patient).
One patient did not receive any treatment, so was excluded
from OS and PFS analyses. Of the 20 patients assessed, the median
follow-up time from PET2 to closeout was 28 months (range, 13–
37 months). For OS, one patient was omitted due to a missing date
of death. For PFS, one patient was omitted due to a missing date of
ﬁrst progression.
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Patients treated radically had a lower risk of death compared with
patients treated palliatively (HR: 0.116; 95% CI: 0.025–0.527,
p < 0.001) (Fig. 2). Of the 19 patients analysed for progression, four
(21%) patients had loco-regionally recurrent lung tumour and se-
ven (37%) had distant disease. Of the eight (42%) patients without0.0 0.5 1.0 1.5 2.0 2.5 3.0
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Fig. 1. Overall survival from PET1, for all patients, regardless of treatment intent
(n = 19), 95% conﬁdence interval shown as broken lines.
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Fig. 2. Overall survival from PET1, comparing patients treated with a palliative and
radical intent (n = 19).
Table 2
t-Tests (log) for change in tumour volumes between scans. GTV: primary gross tumour, G
Measure Mean (PET1) Mean (PET2) Ratio
GTV (cc) 105 198 1.65
GTV1 (cc) 10.0 14.9 1.46
GTV2 (cc) 14.0 32.6 2.30evidence of progression, seven were treated radically. Kaplan–Me-
ier product limit curves for PFS comparing those treated pallia-
tively and radically (Supplementary ﬁle), was also statistically
signiﬁcant with an HR 0.131 (95% CI: 0.034–0.509) p < 0.005 in fa-
vour of radically treated patients.
For the 21 patients assessed, a signiﬁcant increase in the mean
GTV was observed between PET1 and PET2 (p < 0.005) (Table 2).
Mean increases in GTV1 and GTV2 were observed in patients with
node positive disease (Table 2). Changes in the GTV(s) dimensions
necessitated PTV changes in every patient. The 95% CI for the pro-
portion of patients requiring a change in the PTV was thus [84%,
100%]. For all patients, the median [range] PTV was 536 cc [40–
1011 cc] at PET1 and 499 cc [62–3102 cc] at PET2. Fifteen (18%) pa-
tients remained eligible for curative RT following PTV2 and were
included in the planning study. For these patients, the median
[range] PET1 PTV was 378 cc [40–912] and PET2 PTV was 391 cc
[62–971]. A mean increase was observed in all OAR dosimetrics,
except Lung V30 (Table 3). None of these endpoints reached statis-
tical signiﬁcance.Discussion
Our results suggest that delays in radical RT commencement are
associated with signiﬁcant NSCLC progression and worse patient
survival. Patients who received palliative treatment, due to disease
progression detected on PET2, experienced substantially worse OS
and PFS than patients who remained candidates for radical treat-
ment. This ﬁnding augments our previous investigation where ra-
pid pre-treatment progression resulted in palliative treatment for
almost one-third of 28 patients initially eligible for curative RT
[3]. The median survival of the radically treated group was approx-
imately three times longer than that of the palliatively treated
group, a much larger difference than we observed previously
[18,19]. This suggests that although radiation dose may have
played some role in the survival differences observed, there is also
an additional effect due to differences in tumour biology.
Similar ﬁndings were reported by Wang et al. [8] in a larger
study of 237 Stage IIIA/B NSCLC patients [8]. Overall there was
no signiﬁcant effect of time to treatment (TTT) on OS, although a
longer TTT was a signiﬁcant negative prognostic factor in patients
with OS > ﬁve years (HR, 1.029, 95% CI, 1.003–1.055, p = 0.029). In
contrast Bozcuk and Martin [13] reported that time from treatment
referral to commencement (median 48 days) did not affect survival
of 189 NSCLC patients. Similarly, Aragoneses et al. [9] reported no
inﬂuence of delays on the survival of 1082 surgical candidates with
stage I and II NSCLC [9], median delay 35 days (range, 1–154 days).
Salomaa et al. [12] reported that patients delayed longer than the
median TTT (41 days) had a 40% lower risk of dying compared to
patients with a shorter delay (p = 0.020) [12]. There are several
possible explanations for these ﬁndings, all of which depend on a
complex combination of factors including individual tumour
growth kinetics, disease stage and clinician management. A patient
with early-stage disease, despite a long delay, may have a favour-
able prognosis [20]. Some patients may develop more advanced-
stage disease in the TTT, which will adversely affect their chances
of long-term survival. In contrast, treatment initiation for patients
with severely symptomatic disease may be quicker than forTV1: ﬁrst nodal station, GTV2: second nodal station.
estimate 95% CI p-Value Sample size
1.3, 2.0 <0.005 21
0.89, 2.4 0.12 14
1.2, 4.5 0.02 9
Table 3
Changes in OAR dosimetrics between scans.
Measure Mean (PET1) Mean (PET2) Estimate 95% CI Test type p-Value
LV20 (%) 27.7 28.3 0.610 0.81, 2.0 t-Test 0.37
LV30 (%) 24.1 23.7 0.435 2.5, 1.6 t-Test 0.66
MLD (Gy) 16.2 16.7 0.534 0.49, 1.6 t-Test 0.28
Scmax (Gy) 33.2 37.4 1.81 0.43, 6.7 Wilcoxon 0.12
OV50 (%) 19.1 22.4 3.29 4.5, 11 t-Test 0.38
MOD (Gy) 18.8 21.3 2.55 1.3, 6.4 t-Test 0.18
HV40 (%) 19.0 23.5 2.12 1.0, 10 Wilcoxon 0.28
MHD (Gy) 17.3 19.8 2.42 0.59, 5.4 t-Test 0.11
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patients with rapidly progressive disease who would have done
poorly regardless of therapy because of unfavourable biology.
The powerful impact of FDG PET/CT in accurately staging NSCLC
must also be considered when interpreting prior studies. PET/CT
enhances the identiﬁcation of suitable candidates for treatment
by eliminating those with systemic metastatic disease and intra-
thoracic disease too extensive for radical irradiation [21–23] In
turn, only patients who are most likely to beneﬁt from radical ther-
apy are treated aggressively. With due consideration for our lim-
ited sample size, results suggest that PET2 has reliably and
accurately characterised the extent of disease in these patients,
leading to appropriate therapeutic management, and in turn pre-
dicting patient outcomes. Indeed rapid disease progression appears
to be a negative prognostic factor and can only be established with
multiple assessments of disease extent. Larger PET/CT based clini-
cal studies are warranted to examine tumour growth over time
with greater conﬁdence.
Pre-treatment tumour growth also resulted in signiﬁcant in-
creases in GTVs (p < 0.005) and all PTVs. It is likely that such
expansions would have increased the incidence and severity of
radiation-induced toxicities experienced by individual patients
treated radically. This includes increasing oesophagitis resulting
from extensions in radiation portals to encompass primary disease
and positive mediastinal lymph nodes. Although the increases in
dose–volume metrics observed were not statistically signiﬁcant,
the dose response relationship is steep such that small increases
in dose and volume can result in much greater clinical toxicity.
In conclusion, patients who experienced rapid tumour progres-
sion prior to treatment experienced substantially worse OS and PFS
than patients who remained radical candidates. Furthermore, tu-
mour volumes for RT were signiﬁcantly increased to encompass
the increasing extent of tumour between scans. These ﬁndings
highlight the detrimental effects of delaying treatment initiation
on patients and suggest that imaging should be repeated when
there is a long interval between staging and RT commencement.
Additional clinical investigations of PET/CT based tumour progres-
sion in larger patient numbers are required to discern these obser-
vations and their potential impact on patient management and
outcomes.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2013.
02.010.
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